Stocktoria
SAB Biotherapeutics, Inc. SABS
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-01-12
SAB Biotherapeutics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | — | -3244.9% | -1700.6% | -121.0% | -22.0% |
| Net margin | — | -2579.0% | -1884.5% | -78.4% | -28.2% |
| FCF margin | — | -2618.6% | -1130.7% | -107.2% | -14.7% |
| Return on assets | 7.7% | -77.2% | -50.3% | -36.8% | -21.1% |
| Return on equity | 8.8% | -131.3% | -73.6% | -60.3% | -44.5% |
| Current ratio | 9.46 | 2.98 | 5.45 | 1.47 | 1.90 |
| Revenue growth | -100.0% | -40.9% | -90.6% | -60.7% | 10.2% |
Source: SEC EDGAR filings · CIK 0001833214 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.